Evidence map›Paper›PMID 30142953›Full record

ArticleCancers2018

Associations of Epstein-Barr Virus-Positive Gastric Adenocarcinoma with Circulating Mediators of Inflammation and Immune Response.

M Constanza Camargo, Armands Sivins, Sergejs Isajevs, Valdis Folkmanis, Dace Rudzīte, Margaret L Gulley, G Johan Offerhaus, Marcis Leja, Charles S Rabkin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  2. Article
  3. Review
  4. The Human Gastric Juice: A Promising Source for Gastric Cancer Biomarkers.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Predictive markers in gastric cancer immunotherapy treatment-are we there yet?Translational gastroenterology and hepatology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M Constanza CamargoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr., BG 9609/6E338, Bethesda, MD 20892, USA. camargomc@mail.nih.gov.
Armands SivinsInstitute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. armands1@hotmail.com.
Sergejs IsajevsInstitute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. sergisajevs@inbox.lv.
Valdis FolkmanisInstitute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. valdis.folkmanis@lu.lv.
Dace RudzīteInstitute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. dacerudzite2008@inbox.lv.
Margaret L GulleyDepartment of Pathology, University of North Carolina, Chapel Hill, NC 27599, USA. margaret_gulley@med.unc.edu.ORCID 0000-0003-0222-4713
G Johan OfferhausDepartment of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands. g.j.a.offerhaus@umcutrecht.nl.
Marcis LejaInstitute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. cei@latnet.lv.
Charles S RabkinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr., BG 9609/6E338, Bethesda, MD 20892, USA. rabkinc@exchange.nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-positive gastric adenocarcinoma exhibits locally intense inflammation but systemic manifestations are uncertain. Our study examined whether circulating mediators of inflammation and immune response differ by tumor EBV status. From a Latvian series of 302 gastric cancer cases, we measured plasma levels of 92 immune-related proteins in the 28 patients with EBV-positive tumors and 34 patients with EBV-negative tumors. Eight markers were statistically significantly higher with tumor EBV positivity: chemokine C-C motif ligand (CCL) 20 (Odds Ratio (OR) = 3.6;

Indexed as

chemokinesEBVgastric cancerinflammationPD-L1

Identifiers

PMID30142953
PMCPMC6162799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.